NCT05203354 is a Phase 4 clinical trial of Narrowband Ultraviolet B in Psoriasis, sponsored by Mahmoud Ahmed Ali Ahmed.

Who is sponsoring NCT05203354?

NCT05203354 is sponsored by Mahmoud Ahmed Ali Ahmed.

What drugs are being tested in NCT05203354?

Interventions in NCT05203354: Narrowband Ultraviolet B, Acitretin.

Is NCT05203354 still recruiting?

NCT05203354 is currently completed. Last updated 24 January 2022.

Last reviewed 2022-01-24 · How we verify

NCT05203354

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Completed Phase 4 Last updated 24 January 2022

What this trial tests

Phase 4 trial testing Narrowband Ultraviolet B in Psoriasis in 60 participants. Completed in 15 August 2021.

Timeline

1 September 2018

Primary endpoint
1 May 2021

15 August 2021

Quick facts

Lead sponsor	Mahmoud Ahmed Ali Ahmed
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 September 2018
Primary completion	1 May 2021
Estimated completion	15 August 2021
Sites	1 location across Egypt

Drugs / interventions tested

Narrowband Ultraviolet B
Acitretin (ACITRETIN) — full drug profile →

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Mahmoud Ahmed Ali Ahmed

Who can join

Adults 20 to 50, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05203354 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahmoud Ahmed Ali Ahmed
Last refreshed: 24 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing